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Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder of mul-
tipotent hematopoietic stem cells. It is caused by an acquired mutation in the X-
linked phosphatidylinositol glycan class A gene (PIG-A), causing stem cell progeny
(mature blood cells) to lack complement regulatory proteins and exposing them to
complement attack.1 Thromboembolic events are the most common cause of mor-
bidity and mortality in PNH and account for 40-67% of deaths; 40% of patients hav-
ing suffered an event before diagnosis and 29-44% of patients suffering at least one
event throughout the course of their disease.2 Despite such a large role in the burden
of the disease, the mechanism behind the development of thrombosis is poorly
understood, highlighting the importance of thrombosis management in PNH
patients and elucidating more information regarding the nature of the thrombotic
event.3 Multiple proposed mechanisms behind the increased incidence of thrombosis
include a prothrombotic state in conjunction with platelet abnormalities and
impaired fibrinolysis.3,4 The review herein will discuss changes to the hemostatic sys-
tem in PNH, and highlight areas that require future research in the prothrombotic
processes involved in PNH.
Paroxysmal nocturnal hemoglobinuria pathophysiology 
The incidence of PNH is estimated at 0.1–0.2/100,000 persons per year.5 PNH is
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caused by an acquired inactivating mutation of the PIG-A
gene located on the X chromosome. The PIG-A gene codes
for an enzyme involved in the formation of the N-acetylglu-
cosaminyl phosphatidylinositol biosynthetic protein which
is necessary for the first step in the biosynthesis of glyco-
sylphosphatidyinositol (GPI) anchors.6 GPI, a glycolipid
moiety, anchors numerous proteins to the cell surface, with
more than 12 GPI-anchored proteins (GPI-APs) located on
hemopoietic cells.1 Studies have shown the presence of a
small number of GPI anchor deficient cells in the blood of
healthy controls as well as in patients with PNH.7 This
implies that the presence of the PIG-Amutation alone is not
sufficient to allow the PNH clone to dominate. The process
behind the clonal expansion of the PIG-A mutated stem
cells in PNH patients is not fully understood. Two mutually
cooperative hypotheses exist to explain the clonal expan-
sion of PNH cells; one involves immune selection-mediated
expansion and the second predicts that dominant PNH
clones acquire a growth advantage.8 The UL16 binding pro-
tein 1 (ULBP1), a stress-induced ligand for the NKG2D
receptor, is a GPI-linked glycoprotein thought to be lost on
PNH stem cells. Loss of ULBP1 may prevent their destruc-
tion by NKG2D+ lymphocytes allowing for immune-escape
from ULBP-NKG2D engagement in the bone marrow.9 PIG-
A mutant cells have been demonstrated to be less sensitive
to T lymphocytes and, along with leukemic cells with the
same mutation, possess increased resistance to natural killer
cells.9,10 The growth phenotype is thought to be due to the
observed upregulation of the early growth response factor
1 gene (EGR-1) and ectopic expression of the high mobility
transcription factor coding genes HMGA2 has been report-
ed in a few cases.11
The two most significant GPI-APs thought to play a
major role in the pathophysiology of PNH are complement
regulatory proteins CD55 and CD59.12 CD55 interacts with
C4b and C3b and interferes with their ability to analyze the
conversion of C2 and Factor B to active C2a and Bb, thus
preventing the formation of C4b2a and C3bBb (both forms
of C3 convertase). CD59 interacts directly with the mem-
brane attack complex (MAC), formed at the end of the
immune complement cascade, preventing pore formation
and cell lysis.13 The lack of these complement regulatory
proteins allows for complement attack leading to erythro-
cyte lysis, platelet activation and loss of thrombotic modu-
lators on granulocytes, causing many of the symptoms of
PNH.14-16 Exacerbations, or ‘paroxysms’, are sudden increas-
es in symptoms, most noticeably hemoglobinuria and ane-
mia, caused by infection or other inflammatory stimuli.17
Eculizumab, a monoclonal antibody inhibiting C5 cleavage,
has been shown to significantly reduce the symptoms of
PNH as well as associated morbidity and mortality, and is
currently the only licensed treatment for PNH patients.18
Clinical presentation 
Patients may present with ‘classical’ PNH characterized
by clinical and laboratory evidence of intravascular hemol-
ysis with no clinical evidence of an underlying bone mar-
row disorder. Others have evidence of hemolytic PNH as
well as clinical evidence of bone marrow disorder, such as
myelodysplasia or aplastic anemia. A further group may be
defined as ’subclinical PNH’ where a small proportion of
PNH cells are found but with no evidence of hemolysis or
thrombosis.19 The presence of PNH cells is identified using
flow cytometry, determining the  proportion of GPI nega-
tive granulocytes, monocytes and erythrocytes.19 PNH red
blood cells can be labeled type I, II or III; type I cells have
normal expression of GPI-APs, type II have partial deficien-
cy and type III lack all GPI-APs.20
The clinical manifestations are variable; intravascular
hemolysis, thrombosis and anemia are significant, howev-
er, other symptoms may be present.1 Schrezenmeier et al.
analyzed 1610 patients and showed the proportion of
symptoms, such as fatigue (80%), dyspnea (64%), hemo-
globinuria (62%), abdominal pain (44%), chest pain (33%)
and impaired renal function (14%), with only 16% of
patients having a history of thrombotic events.21 However,
Hill et al. have shown that the presence of subclinical
thrombosis is significantly underestimated.22
The ongoing effect of intravascular hemolysis, as previ-
ously described, is responsible for causing most of the
symptoms in PNH (Figure 1). Intravascular hemolysis
results in the release of free hemoglobin which is normally
cleared by haptoglobin, hemopexin and the scavenger
CD163. These clearing mechanisms are overwhelmed in
PNH and lead to the accumulation of high levels of free
hemoglobin in the plasma, resulting in the scavenging and
depletion of nitric oxide (NO).23 The subsequent excess of
hemoglobin leads to the visible hemoglobinuria, while the
depletion of NO, a potent vasodilator, results in vasocon-
striction, decreased regional blood flow and muscular con-
traction, causing chest and abdominal pain, amongst other
symptoms.3 Moyo et al. reported significant differences in
the proportion of PNH cells in patients with symptoms of
abdominal pain, hemoglobinuria and esophageal spasm
(causing chest pain and dysphagia). The mean proportion
of PNH granulocytes in patients with these symptoms was
at least twice that of patients who did not possess these
clinical manifestations.24
As previously described, thrombosis is the most serious
complication associated with PNH. Thrombotic events are
reported to be of venous origin in 85% of cases, arterial in
15% of cases and involve more than one site at the same
time in 20.5% of cases.5 Thrombosis can occur at any site,
with deep vein thrombosis, pulmonary embolism, myocar-
dial infarction or cerebral vascular attack all commonly
observed complications.25 There appears to be an increased
incidence of thrombosis at atypical sites, such as the hepatic
vein resulting in Budd-Chiari syndrome, occurring in 40-
44% of PNH patients, in addition to thrombosis in the vas-
culature of the central nervous system, mesenteric, dermal
veins and the cavernous sinus.26 The proportion of PNH cells
and clone size has also been associated with thrombotic
complications. Hall et al. demonstrated that in patients with
a proportion of PNH granulocytes greater than 50%, the 10-
year risk of thrombosis was 44%, but in patients with a pro-
portion of PNH granulocytes less than 50% the risk was
5.8%.27 Through logistical regression, Moyo et al. calculated
the increase in odds ratio for thrombosis to be 1.64 for each
10% increase in the proportion of PNH cells.24 These find-
ings correlate with other studies which have shown that the
occurrence of thrombosis is noticeably elevated in PNH
patients with a proportion of PNH cells as low as 10% when
compared to normal population controls.28,29
Platelet activation
The mechanisms behind thrombus formation in PNH are
complex and subject to continued research. Interactions
between the complement system, platelets and coagulation
likely explain some of the increased risk of thrombosis. Due
to the multifactorial and variable nature of the disease, it is
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likely that a combination of several factors may contribute
to the increased incidence of thrombus formation and asso-
ciated mortality (Figure 2). 
Platelets have been reported to play a significant role in
the formation of thrombus in PNH patients, by both con-
tributing to a prothrombotic state and initiating clot forma-
tion.30 One would expect that due to the deficiency of
CD55 and CD59, lysis of platelets occurs and contributes to
thrombocytopenia. However, this is not the case, as the
lifespan of platelets in PNH patients is normal.31 Rather than
complement resulting in the lysis of platelets, an intrinsic
mechanism of adaption and resistance to complement
attack has been observed which subsequently contributes
to the prothrombotic state.32 It has been shown that upon
increased deposition of MAC (C5b-9) on the membrane of
platelets, rather than lysis, complement accumulation on
the platelet surface triggers morphological changes.15 The
loss of platelet membrane phospholipid asymmetry
through the action of an adenosine triphosphate (ATP)-
dependent enzyme, gelsolin, aminophospholipid translo-
case, lipid scramblase and calpain allow for cytoskeletal and
phospholipid bilayer changes.33 The now activated platelet
secretes α-granules, and in conjunction with membrane
depolarization, α-granules fuse with the platelet mem-
brane.34 This results in exocytosis of the vesiculated MAC
and the production of prothrombotic platelet-derived
microparticles (PMPs).15
Platelet-derived microparticles 
The exact role of PMPs is not fully understood, however,
they are considered to play a role in the generation of a pro-
thrombotic state in PNH.15 Three key hypotheses for the
prothrombotic nature of PMPs have been identified.35 First,
platelet microparticles are formed by platelets upon activa-
tion, therefore their membranes possess the same pro-
thrombotic properties as the activated platelet membrane.36
Second, PMPs can bind clotting cascade components, such
as activated factors V (Va) and VIII (VIIIa); furthermore, the
densities of these protein binding sites on PMPs appear to
exceed those on activated platelet membranes.37,38 Finally,
when isolated PMPs are added back to platelet free pooled
plasma without the addition of coagulation activators, they
trigger thrombin generation, demonstrating that micropar-
ticles generated in vivo can stimulate coagulation.39
Sinauridze et al. estimated that PMP membranes have a 50-
to 100-fold higher specific procoagulant activity than acti-
vated platelets.35
PMPs have been shown to express many of the following
membrane binding protein complexes which are normally
observed on activated platelets: glycoprotein Ib (GPIb),
which binds von Willebrand factor (VWF) initiating forma-
tion of the platelet plug;40 platelet endothelium adhesion
molecule (PECAM-1), an immunoglobulin superfamily
member involved in leukocyte transmigration, angiogenesis,
and integrin activation;41 the integrin glycoprotein IIb/IIIa
(GpIIb-IIIa) or αIIbβ3, a receptor for fibrinogen and VWF, fur-
ther aiding platelet aggregation and plug formation;42 and P-
selectin, a cellular adhesion molecule which exacerbates
symptoms via a feedback loop through continued stimula-
tion of the alternative pathway, initiating activation of the
classical pathway as well as stimulating further platelet
aggregation.43 The expression of membrane proteins
involved in thrombus formation on platelet microparticles
suggests an ability to contribute to the prothrombotic state.
Multifaceted prothrombotic state in PNH
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Figure 1. Summary of the multiple factors thought to contribute to the prothrombotic state in paroxymal nocturnal hemoglobinuria (PNH) and interaction. Further
details are provided in the text. MAC: membrane attack complex; NET: neutrophil extracellular traps; TFPI: tissue factor pathway inhibitor; VWF:  von Willebrand factor;
WPB: Weibel-Palade bodies; NO: nitric oxide; ROS: reactive oxygen species; TF: tissue factor.
However, further studies are necessary to analyze and quan-
tify their specific role in PNH-induced risk of thrombosis. 
Phosphatidylserine is expressed on the surface of platelet-
derived microparticles as a result of MAC binding-induced
morphological changes.44 Phosphatidylserine is normally
confined to the inner leaflet of the platelet membrane, how-
ever, it is translocated to the outer leaflet due to the action
of the lipid scramblase enzyme and exposed as a result of
platelet activation.33 Phosphatidylserine interacts via posi-
tively charged calcium ions with negatively charged γ-car-
boxyglutamic acid (GLA) domains in vitamin K-dependent
clotting factors, e.g. VII (FVII), IX, X, and prothrombin.45
This catalyzes the formation of the procoagulant enzyme
complexes prothrombinase (VaXa) and tenase (VIIIaIXa),37
and allows for the accelerated conversion of prothrombin
to thrombin and stimulation of the coagulation cascade.44
Coagulopathy has been observed in patients with
Castaman defect and Scott syndrome, and is thought to
result from defects in the action of scramblases to translo-
cate phosphatidylserine to the membrane surface.46,47
Residual activated platelets
The prothrombotic properties of residual activated
platelets (platelets post microparticle production) is still a
matter of discussion. Activated platelets in PNH patients
have been shown to possess greater than ten times the fac-
tor V binding sites compared with those from normal con-
trols.16 Activated platelets have been shown to promote
thrombus formation through neutrophil interaction, result-
ing in the release of serine proteases and nucleosomes, acti-
vating Factor X.48 Like their exocytosed microparticles, acti-
vated platelets also express P-selectin, which is thought to
further stimulate the complement pathway.49 Surprisingly,
a study by Grünewald et al. found evidence of hyporeac-
tive platelets in PNH.50 It is possible that the failure of acti-
vated platelets to bind fibrinogen, VWF and to aggregate is
due to receptor GpIIb-IIIa complexes in proximity to MAC
pores becoming uncoupled from the intracellular transduc-
tion mechanisms normally involved in their activation.37
This observation was consistent with the findings of
Gralnick et al., who reported variable amounts of platelet
activation and further observed reduced VWF binding.30
Grünewald et al. hypothesized a mechanism of dual
causality responsible for platelet hyporeactivity.50 One
mechanism is hyperstimulation of platelets due to sus-
tained complement attack.16,37,50 Chronic hyperstimulation
of the coagulation system was hypothesized to further
downregulate the activity of activated platelets.4,50 This
highlights the complex variable nature of thrombosis in
PNH, suggesting that platelets post activation possibly
have a diminished role in PNH-induced thrombosis in
comparison to other thrombotic diseases.
Hemolysis 
As well as contributing to a wide array of symptoms in
PNH, hemolysis is thought to contribute to a prothrombot-
ic state, but its role is becoming increasingly scrutinized.51
Erythrocytes have been reported to produce microparticles
as a result of MAC-induced apoptosis.52 Some microparti-
cles observed in PNH have indeed been confirmed to origi-
nate from erythrocytes; however, Hugel et al. reported that
this was not ‘to a significant extent’ while ‘very high levels’
of microparticles of platelet origin were detected.15 Two
studies have concluded that the level of erythrocyte
microparticles produced in PNH patients was similar to
healthy controls;15,53 hence, it is possible that the contribu-
tion of erythrocyte microparticles to the prothrombotic
state in PNH is only minimal.
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Figure 2. Hemostasis mecha-
nisms in paroxymal noctur-
nal hemoglobinuria (PNH)
patients are imbalanced
towards thrombosis. NET:
neutrophil extracellular traps;
WPB: Weibel-Palade bodies;
ROS: reactive oxygen species;
NO: nitric oxide. 
Free Hemoglobin and Endothelial Dysfunction 
Excess free hemoglobin is a further possible mechanism
that may underpin the prothrombotic state in PNH. Upon
intravascular hemolysis, free hemoglobin is rapidly bound
to the serum protein haptoglobin expressed on mono-
cytes/macrophages forming a complex which is then
endocytosed and degraded by CD163.24,54,55 The oxygen
binding component of hemoglobin, ferrous heme, can be
oxidised to ferric heme, resulting in rapid binding to
hemopexin.56 The resulting reaction has vasodilatory,
antiproliferative, anti-inflammatory, and antioxidant prop-
erties through the release of carbon monoxide, the
biliverdin metabolite biliverdin reductase, and the uptake
of anti-inflammatory interleukin-10 and heme oxygenase
into circulating monocytes.54,57 The scavenging mecha-
nisms described above can become saturated resulting in
increased levels of free hemoglobin in the circulation,
leading to a prothrombotic state in addition to other
symptoms.23,24
There is increasing evidence supporting possible pro-
thrombotic effects of free hemoglobin on platelets and the
vascular endothelium.58 A recent study by Belcher et al.
showed that heme rapidly stimulates the release of
Weibel-Palade bodies (WPBs) from the vascular endotheli-
um.59 Degranulation of WPBs releases VWF and P-selectin
onto the surface of endothelial cells, stimulating coagula-
tion and the complement cascade.59 In vivo studies have
demonstrated that the infusion of crosslinked hemoglobin
increased platelet aggregation and adhesion to the
endothelium of an injured vessel wall.60 Free hemoglobin
has been observed to directly bind to VWF exposed on the
endothelium which increases its affinity for the glycopro-
tein Ib (GPIb) receptor on the surface of platelets.61
Conjointly, the addition of free hemoglobin to human
serum causes inhibition of the VWF cleaving protease
ADAMTS13, an enzyme critical in limiting platelet throm-
bus formation.62,63 Heme administration in healthy volun-
teers has been demonstrated to cause thrombophlebitis,
vascular inflammation and obstruction.64
Patients with PNH have also been observed to possess
increased levels of endothelial-derived microparticles
(EMPs).40,65 GPI-deficient monocytes are thought to release
microparticles rich in tissue factor (TF) upon complement
damage.66 Uptake of monocyte-derived microparticles
concomitantly increased endothelial TF expression while
producing EMPs. Two separate studies have observed
increased levels of EMPs in patients with PNH.40,67 The
number of EMPs produced relative to PMPs is thought to
be small, and as such its contribution to the prothrombotic
state is minimal.53 Further procoagulant effects of endothe-
lial cells result from prolonged exposure to free heme.68
Endothelial exposure to heme induces tissue factor expres-
sion, which can initiate coagulation, and also activates
expression of intracellular adhesion molecule 1 (ICAM1),
vascular cell adhesion molecule (VCAM1), and E-
selectin.69 The now activated endothelial cells recruit
inflammatory cells, promoting thrombus formation at the
vessel wall.23 This can be further enhanced by pro-inflam-
matory cytokines and chemokines which have been
observed as being over-expressed in other hemolytic dis-
orders.70 It is still unknown whether bone marrow-derived
endothelial cells in PNH patients harbor the GPI-AP defi-
ciency.66 Tissue factor pathway inhibitor (TFPI) inhibits
tissue factor and therefore coagulation.71 It is predomi-
nantly produced by the endothelium (85%), however,
platelets, monocytes and plasma are other sources.66,71
TFPI is expressed in two isoforms, TFPI-α and TFPI-β.72 It
is still disputed which TFPI isoform is the most abundant-
ly expressed isoform, however TFPI-β, a GPI-AP
expressed on ECs, is thought to exert 80% of anticoagu-
lant activity.72,73 Possible deficiency of the GPI anchor of
TFPI-β in PNH may therefore reduce the anticoagulant
properties of the endothelium in PNH and contribute to
thrombus formation.74,75
Anti-thrombin is enhanced by binding to the heparan
sulphate receptor, a GPI-linked protein expressed on
endothelial cells and hypothesized to be lost in patients
with PNH.76 As the heparin sulphate receptor is GPI-
linked, its loss is thought to contribute to a prothrombotic
state. No studies have fully investigated the significance of
the heparan sulphate receptor, however, a compensatory
mechanism has been suggested after there was no change
in fibrin deposition in animal studies of heparan sulphate
deficiency.77
Reactive oxygen species
Free hemoglobin has also been demonstrated to pro-
duce reactive oxygen species (ROS) via two mechanisms:23
the  amphipathic heme interacts with the phospholipid
membrane, and via the Fenton reaction catalyzes the pro-
duction of ROS,78 and extracellular hemoglobin autoxi-
dizes to methemoglobin catalyzed by peroxidase
enzymes which further generates ROS.79 A study by Amer
et al. has also shown that PNH cells have a higher oxida-
tive status when compared to normal cells.80 It is not clear
if this is as a result of free hemoglobin, platelet hyperactiv-
ity (as previously discussed) or a pre-existing defect in
PNH cells that exacerbates these pathologies, thus, further
research into this area is necessary. The formation of ROS
is well-documented to produce phospholipid disorganisa-
tion, induce cytotoxicity and promote inflammation,23,81
and studies have also shown that ROS can directly
enhance platelet activation.82 The Fenton reaction also
activates protein kinase C as well as ROS which have
been demonstrated to activate platelets.82
Neutrophils and monocytes
Neutrophils have also been reported to contribute to the
prothrombotic mechanisms in PNH.23,56 ROS produce neu-
trophil extracellular traps (NETs), exposed extracellular
chromatin with peripherally attached enzymes.59
Extracellular chromatin has been observed as a structural
component in deep vein thrombi as well as contributing to
the pathogenesis involved in their formation.83 Studies
have found that histones, which are also released from
NETs, increase thrombin generation and platelet activa-
tion by impairing the activation of protein C.84 The impair-
ment of protein C activation in turn prevents the inactiva-
tion of clotting FV and FVIII which, as examined previous-
ly, form the prothrombinase and tenase complexes,
respectively, on platelets.85 Recent studies have demon-
strated a specific link between NETs and the formation of
venous thrombosis. This mechanism may explain the
high prevalence of thrombi in veins at atypical sites and
warrants further study in PNH.83,84 The membrane attacks
complex formation on the surface of monocytes and neu-
trophils and is also thought to contribute to the procoagu-
lant state in PNH.3,23 Complement-induced cell activation
results in the expression of tissue factor as well as plas-
minogen activator inhibitor 1, contributing to thrombus
Multifaceted prothrombotic state in PNH
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formation while impairing fibrinolysis (discussed below).86
Proteinase 3 (PR3), an enzyme thought to reduce throm-
bin-induced platelet activation binds to the GPI-anchored
co-factor NB1 (CD177) expressed on neutrophils.87 A defi-
ciency of NB1 may therefore contribute to platelet activa-
tion and exacerbate the procoagulant state through prote-
olysis of the protein C receptor, degradation of TFPI and
upregulation of TF expression on endothelial cells.88-90
Prothrombotic feedback mechanisms
Thrombin, the generation of which is increased by
many of the mechanisms described above, has been
observed to independently activate complement proteins
C3 and C5.91 Plasmin, an enzyme involved in fibrin clot
degradation and stimulated by fibrin itself, has also recent-
ly been shown to cleave C5.92 This suggests a feedback
mechanism in which thrombin generation, fibrin deposi-
tion and fibrinolysis may in turn activate the complement
system, which reciprocally leads to more platelets and
coagulation activation, exacerbating the thrombotic
response (see Figures 1 and 2 for a summary of prothrom-
botic mechanisms involved in PNH).93 Plasmin has been
shown in vitro to initiate the synthesis of platelet activating
factor (PAF) from endothelial cells,94 while a further in vivo
study has shown a correlation between the concentration
of the terminal complement complex (C5b-9) and PAF.
This may begin to highlight a mechanism in which the
MAC contributes to plasmin-induced synthesis of PAF in
endothelial cells, however, it is unclear whether this
would contribute to thrombosis or platelet
hyporeactivity.95
Nitric oxide depletion
Hemoglobin and nitric oxide (NO) bind in an irre-
versible reaction, the rate of which is suggested to increase
by up to 500-600 times as a result of intravascular hemol-
ysis and the loss of heme compartmentalization.96
Intravascular hemolysis also releases arginase which
breaks down L-arginine, the substrate for NO synthesis.97
NO depletion has been well-established as a potent regu-
lator of smooth muscle tone, causing vascular constriction
and contributing to a prothrombotic state.1,3,56 One study
has found a 12-fold increase in the consumption of NO in
PNH patients when compared to healthy volunteers in
addition to an increase in pulmonary hypertension.98 As
well as having a vasodilatory effect, NO also binds to
platelets, causing signal transduction that downregulates
the expression of the fibrinogen binding integrin glycopro-
tein IIb/IIIa, reduces levels of intracellular calcium and
inhibits platelet activation.99,100 A reduction in circulating
NO results in further dysregulation of platelets, and, com-
bined with local vasoconstriction can contribute to
intravascular thrombosis.56
Fibrin clot structure
There is a growing body of evidence in the literature
that individuals with an increased risk of thrombosis form
fibrin clots with an altered 3-dimensional structure.101 The
altered clot structure is comprised of thinner but more
tightly packed fibrin fibers, which, possibly combined
with fewer binding sites for plasmin and tissue plasmino-
gen activator (tPA), leads to impaired fibrinolysis. The
dense clot structures are more resistant to fibrinolysis due
to the increased number of fibers that need to be lysed and
a reduced permeation of the lytic enzymes into the denser
clot structure.102 Moreover, clots with densely packed
fibers are stiffer and more resistant to mechanical defor-
mation.103 Due to these structural and functional changes,
dense clots with smaller pores are associated with an
increased risk of thrombosis. There have been no studies
to date that have investigated clot structure in patients
with PNH. Abnormal clot structure could be an additional
mechanism by which the risk of thrombosis is increased
in PNH, deserving further study.  
Additionally, the link between PNH and clot structure
may be of interest, since complement activation and fac-
tors have been associated with effects on fibrin clot struc-
ture and function. For example, alternative complement
pathway activation has been associated with the produc-
tion of denser, more tightly packed clots;104 furthermore,
C3 has been shown to be incorporated into the fibrin clot,
leading to thinner fibrin fibers and a stiffer clot with
increased resistance to fibrinolysis.105 In addition, MASP-1
has been shown to influence clot formation and activate
coagulation Factor XIII, leading to an increased resistance
of the clot to fibrinolysis.106 There may yet be other,
unidentified mechanisms by which complement activa-
tion may regulate clot structure and function. 
High plasma levels of fibrinogen, the molecular precur-
sor to fibrin, are known to affect clot structure.107 Seregina
et al. measured fibrinogen levels in PNH patients pre- and
post-treatment with eculizumab (n=3), and found no dif-
ference from normal controls.18 This suggests that clot
structure is not being modulated by high levels of fibrino-
gen in PNH patients, but the small sample size means fur-
ther study is necessary. 
Studies have shown that high concentrations of throm-
bin during fibrin clot formation results in prothrombotic
fibrin structure and more stable clots.108 Surprisingly, one
study found lower levels of thrombin generation in PNH
patients. However, this may have been partly caused by
the fact that thrombin generation in this study was meas-
ured in the absence of platelets and endothelial cells,
which have been shown to be activated in PNH and
enhance thrombin generation, as previously discussed.75
An alternative study found significantly elevated levels of
thrombin generation on endothelial cells in patients with
PNH.67 As examined previously, both activated platelets,
PMPs and NETs increase thrombin generation and, there-
fore, may modulate clot structure through increased
thrombin generation. Oxidized red blood cells integrated
into fibrin clots have also been observed, enhancing clot
stability.109 The oxidation of fibrin fibers has also been pro-
posed to alter clot structure; however, this has been
shown to both impair fibrin formation as well as produce
thinner fibers and weaker clots.110
The role of microparticles in modulating clot structure is
still a matter of dispute. Aleman et al. found that while
platelet microparticles appeared to have no effect on clot
structure, monocyte-derived microparticles supported
faster fibrin deposition and a denser, more stable fibrin
clot.111
Impaired fibrinolysis 
Impaired fibrinolysis has been indicated in patients with
PNH.3,4,66 Urokinase-type plasminogen activator receptor
(uPAR) is a GPI-AP, and as such is absent from PNH mono-
cytes and granulocytes.112 This results in increased plasma
levels of free uPAR protein, which is thought to compete
with the membrane bound uPA receptor, competitively
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inhibiting cell-based plasmin generation and therefore
contributing to a prothrombotic state in PNH.113,114 As dis-
cussed above, neutrophils, when activated, can express
plasminogen activator inhibitor-1, impairing plasminogen
and urokinase and therefore inhibiting fibrinolysis.
Studies have also observed activated platelets releasing
inhibitory proteases, plasminogen activator inhibitor-1
and α2-antiplasmin.115 More studies are needed to identify
further causes of impaired fibrinolysis, whether it be
resulting from GPI-AP loss or the hyperactivity of pro-
thrombotic cells. 
Animal models 
Mouse models have been used in the study of PNH,
however it has proven difficult to replicate the thrombot-
ic sequelae resulting from CD55 and CD59 deficiency.
Complications arise due to the fact that there are two dif-
ferent CD55 and CD59 coding genes, a and b, respective-
ly, and as a result, isolating their respective phenotypes
following knockout has proven challenging.116,117 Mice
also possess a unique transmembrane protein, comple-
ment-receptor 1-related gene protein (Crry), a functional
homolog of human membrane co-factor protein which
plays a critical role in protecting developing fetuses in
mice from lethal complement attack. It has only been
possible to produce Crry/C3 double knockout mice,
which showed evidence of extravascular hemolysis,
however, mice erythrocytes and platelets lacking Crry
have been demonstrated to be more susceptible to
hemolysis.118,119 Generating PIG-A mutations has proven
difficult, as PIG-A deletion in embryonic stem cells is
lethal.120 A PIG-A floxed mosaic mice model was generat-
ed with the coexistence of normal and mutated cells
mimicking PNH patients, however, the PNH clone failed
to clonally expand and produce PNH symptoms.121 Kellet
et al. succeeded in creating a model with 100% of red
blood cells being GPI-AP negative, however, no symp-
toms of PNH were observed. Limited knowledge of the
clonal expansion mechanism has made it difficult to cre-
ate animal models in which the thrombotic mechanisms
in PNH can be analyzed. Future studies into clonal expan-
sion mechanisms may lead to the development of more
appropriate in vivo models, enabling the study of the
mechanisms of thrombosis in PNH.
Summary and future perspectives 
Thrombosis risk is greatly increased in patients with PNH
and is the greatest cause of morbidity and mortality in the
disease. However, the mechanisms underpinning this are
far from clear and are likely to be different from those of
other thrombotic disorders. The prothrombotic state in
PNH is extremely complex, with many different factors
resulting from platelet activation, intravascular lysis and
neutrophil/monocyte activation all thought to play a role.
Further research is necessary in order to quantify how
much each of these factors contribute to the prothrombotic
state as well as to analyze their role in vivo. The newly
hypothesized role of NETs especially warrants investiga-
tion, as this may explain the high and sustained incidence
of atypical thrombosis in PNH. Impaired fibrinolysis and
alterations to clot structure also appear to be hallmarks of
thrombotic events, and it is important to determine the role
of eculizumab in modifying these. Further identification of
GPI-APs involved in clot structure and impaired fibrinolysis,
as well as clarification as to whether endothelial cells lack
GPI-APs, is necessary in order to understand the complex
mechanism of thrombosis in PNH. With PNH research now
in the post-eculizumab era, our understanding of the com-
plement-mediated disease processes has improved dramat-
ically, but those underpinning thrombotic complications are
still insufficiently understood, despite the many hypotheti-
cal mechanisms which have been proposed. Future studies,
including those involving animal models of PNH, may help
to address this hiatus while simultaneously highlighting
similar prothrombotic mechanisms in other, related
hemolytic complement diseases. Identifying the factors that
most significantly contribute to thrombus formation in
PNH would allow for the application of more targeted ther-
apies, potentially minimizing the disease burden and fur-
ther improving patient outcomes. 
Multifaceted prothrombotic state in PNH
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